CD274 and non-small cell lung carcinoma: Clinically relevant changes in the PD-L1 TPS were observed in 17% of the advanced NSCLC patients, and the PD-L1 TPS was found to be much higher in patients treated with chemotherapy than in those treated with immunotherapy (Frank et al., 2020).